QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.049395v2 306/1/253    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cirillo, R. Articles by Chollet, A. Search for Related Content PubMed PubMed Citation Articles by Cirillo, R. Articles by Chollet, A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB OXYTOCIN PROSTAGLANDIN F2ALPHA

ENDOCRINE AND REPRODUCTIVE

Pharmacology of (2S,4Z)-N-[(2S)-2-Hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a New Potent and Selective Nonpeptide Antagonist of the Oxytocin Receptor

Istituto di Ricerche Biomediche "A. Marxer", LCG Bioscience, Colleretto Giacosa, Italy (R.C., E.G.T., F.B., C.G., L.G., P.M.); Institut National de la Santé et de la Recherche Médicale U469, Montpellier, France (C.C., F.L., K.P., C.B.); Evotec OAI, Milton Park, Abingdon, United Kingdom (R.J.T.); and Serono Pharmaceutical Research Institute, Geneva, Switzerland (M.K.S., A.Q., A.S., M.M., J.D., A.N., A.C.)

We have discovered a new, potent, selective, and orally active oxytocin receptor antagonist, (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide (compound 1). We report the biochemical, pharmacological, and pharmacokinetic characterization in vitro and in vivo of this compound. Compound 1 competitively inhibits binding of [³H]oxytocin and the peptide antagonist ¹²⁵I-ornithine vasotocin analog to human and rat oxytocin receptor expressed in human embryonic kidney 293-EBNA or Chinese hamster ovary cells with nanomolar potency. Selectivity against vasopressin receptor subtypes is >6-fold for V1a and >350-fold for V2 and V1b. Compound 1 inhibits oxytocin-evoked intracellular Ca²⁺ mobilization (IC₅₀ = 8 nM). Compound 1 has no intrinsic agonist activity at the oxytocin receptor. Oxytocininduced contraction of isolated rat uterine strips is blocked by compound 1 (pA₂ = 7.82). In anesthetized nonpregnant rats, single administration of compound 1 by i.v. or oral routes causes dose-dependent inhibition of contractions elicited by repeated injections of oxytocin with ED₅₀ = 3.5 mg/kg i.v. and 89 mg/kg p.o., respectively. Compound 1 significantly inhibits spontaneous uterine contractions in pregnant rats near term when administered intravenously or orally. We conclude that compound 1 is a potent, selective, and orally active nonpeptide oxytocin receptor antagonist, which is a suitable candidate for evaluation as a potential tocolytic agent for the management of preterm labor.

Address correspondence to: Dr. André Chollet, Serono Pharmaceutical Research Institute, 14, Chemin des Aulx, CH-1228 Plan-les-Ouates, Geneva, Switzerland. E-mail: andre.chollet{at}serono.com

This article has been cited by other articles:

				G. P. McCafferty, M. A. Pullen, C. Wu, R. M. Edwards, M. J. Allen, P. M. Woollard, A. D. Borthwick, J. Liddle, D. M. B. Hickey, D. P. Brooks, et al. Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R299 - R305. [Abstract] [Full Text] [PDF]

				T. M. Goodwin The Gordian Knot of Developing Tocolytics Reproductive Sciences, September 1, 2004; 11(6): 339 - 341. [PDF]

				C. Serradeil-Le Gal, G. Valette, L. Foulon, G. Germain, C. Advenier, E. Naline, M. Bardou, J.-P. Martinolle, B. Pouzet, D. Raufaste, et al. SSR126768A (4-Chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, Hydrochloride): A New Selective and Orally Active Oxytocin Receptor Antagonist for the Prevention of Preterm Labor J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 414 - 424. [Abstract] [Full Text]